Global

News Release Archive

This section features CSL Behring news releases that are more than 18 months old. Click the tabs to select releases in your area of interest. Click Resources to find additional background material on CSL Behring.

All Releases
Corporate
Immunology
Bleeding Disorders
Hereditary Angioedema (HAE)
Pulmonary
Fluid Management
Resources

All Releases

29 February 2016 CSL Behring’s Long-acting rIX-FP for Hemophilia B - IDELVION® - Receives Positive Opinion from European Medicines Agency CHMP

Global biotherapeutics leader CSL Behring announced today that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended granting marketing authorization for IDELVION® (Coagulation Factor IX (Recombinant), Albumin Fusion Protein) for patients with hemophilia B.

> Read More
24 February 2016 CSL Behring Adds Isoagglutinin Reduction Step to Privigen® Manufacturing Process

Global biotherapeutics leader CSL Behring today announced an enhancement to its manufacturing process for Privigen® with the addition of the Ig IsoLo® step.

> Read More
23 February 2016 First Export of Privigen® From New Manufacturing Facility in Broadmeadows, Melbourne, Australia

Global biotherapeutics leader CSL Behring today announced an increase in the global supply of Privigen® as the first export has been shipped from a new state-of-the-art manufacturing facility in Broadmeadows, Melbourne, Australia.

> Read More
02 February 2016 CSL Behring and Its Employees Pass $1 Million Mark in Charitable Donations to Communities Throughout the U.S.

CSL Behring’s U.S. locations in King of Prussia and Kankakee, Il., and its subsidiary, CSL Plasma headquartered in Boca Raton, Fla., raised more than $1 million in 2015 for a wide array of charities, setting a new company record.

> Read More
22 December 2015 CSL Behring Submits Marketing Authorization Application to the European Medicines Agency for rVIII-SingleChain for Patients with Hemophilia A

Global biotherapeutics leader CSL Behring announced today that the company has submitted its Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for its novel investigational recombinant factor VIII single-chain (rVIII-SingleChain) for the treatment of hemophilia A. In the pivotal clinical trial, rVIII-SingleChain met all primary endpoints.

> Read More
Page 4 of 53 First | Previous | Next | Last

Share
LinkedIn Twitter Facebook Google+